Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
LEXX 
Lexaria Bioscience Corp (LEXX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: LEXX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Year Target Price $7
Year Target Price $7
| 0 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit -15.03% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 16.61M USD | Price to earnings Ratio - | 1Y Target Price 7 |
Price to earnings Ratio - | 1Y Target Price 7 | ||
Volume (30-day avg) - | Beta 0.94 | 52 Weeks Range 0.82 - 4.38 | Updated Date 06/29/2025 |
52 Weeks Range 0.82 - 4.38 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.61 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1581.04% |
Management Effectiveness
Return on Assets (TTM) -77.6% | Return on Equity (TTM) -145.55% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 10186616 | Price to Sales(TTM) 31.57 |
Enterprise Value 10186616 | Price to Sales(TTM) 31.57 | ||
Enterprise Value to Revenue 19.37 | Enterprise Value to EBITDA -7.22 | Shares Outstanding 19559200 | Shares Floating 16302820 |
Shares Outstanding 19559200 | Shares Floating 16302820 | ||
Percent Insiders 7.03 | Percent Institutions 6.36 |
Analyst Ratings
Rating 4 | Target Price 7 | Buy 2 | Strong Buy - |
Buy 2 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Lexaria Bioscience Corp
Company Overview
History and Background
Lexaria Bioscience Corp. was founded in 2004. Initially focused on chocolate products, it pivoted to drug delivery technology. Significant milestones include developing DehydraTECH and focusing on nicotine and hypertension applications.
Core Business Areas
- DehydraTECH Platform: Lexaria's core business is the DehydraTECH drug delivery technology. It enhances the bioavailability and speed of onset of orally administered drugs, nutraceuticals, and nicotine.
- Pharmaceutical Applications: The company is focused on using DehydraTECH to treat conditions such as hypertension and dementia, with clinical trials underway.
- Nicotine Delivery: Lexaria explores applications of DehydraTECH for improved nicotine delivery, primarily through alternative forms like pouches.
Leadership and Structure
Chris Bunka serves as CEO. The company has a board of directors and a scientific advisory board guiding its research and development efforts.
Top Products and Market Share
Key Offerings
- DehydraTECH: DehydraTECH is not sold directly as a product but licensed to other companies for use in their formulations. Market share is difficult to quantify as it's embedded in other products. Competitors include NanoSphere Health Sciences, and other companies with nano-emulsion technologies.
- DehydraTECH-CBD: DehydraTECH delivery of CBD is their own product, and it shows clinical promise for oral delivery and bioavailability. Their competition in this space includes water soluable CBD, and other emulsified CBD products. It is also hard to quantify market share because it is an ingredient in other products.
Market Dynamics
Industry Overview
The drug delivery technology industry is experiencing growth driven by demand for improved drug efficacy and patient compliance. The nutraceutical and nicotine industries also seek enhanced delivery methods.
Positioning
Lexaria positions itself as an innovator in drug delivery, emphasizing DehydraTECH's advantages in bioavailability and speed of onset. It competes with other drug delivery technologies and focuses on licensing agreements.
Total Addressable Market (TAM)
The TAM for drug delivery systems is estimated to be in the tens of billions of dollars. Lexaria is positioning itself to capture a portion of this market through licensing agreements and pharmaceutical development.
Upturn SWOT Analysis
Strengths
- Proprietary DehydraTECH technology
- Improved bioavailability and onset speed
- Potential for multiple applications (pharmaceutical, nutraceutical, nicotine)
- Patent protection
- Clinical trial progress
Weaknesses
- Limited revenue generation
- Reliance on licensing agreements
- High research and development costs
- Dependence on successful clinical trials
- Small company size and resources
Opportunities
- Expanding licensing agreements
- Successful clinical trial outcomes
- Partnerships with pharmaceutical companies
- Market growth in nutraceuticals and nicotine alternatives
- New applications for DehydraTECH
Threats
- Competition from established drug delivery technologies
- Regulatory hurdles
- Failure of clinical trials
- Patent infringement
- Market acceptance of DehydraTECH
Competitors and Market Share
Key Competitors
- CRBP
- ABBV
- MRNA
- LLY
Competitive Landscape
Lexaria has a unique drug delivery technology but faces competition from established pharmaceutical companies with broader product portfolios and greater financial resources. Lexaria's advantage lies in its specific technology and its licensing model.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by technological development and clinical trials rather than revenue. Recent growth has come from partnerships and research.
Future Projections: Future growth depends on the success of clinical trials, licensing agreements, and market adoption of DehydraTECH. Analyst estimates are not readily available.
Recent Initiatives: Recent initiatives include clinical trials for hypertension and dementia, securing new patents, and pursuing licensing agreements.
Summary
Lexaria Bioscience is a promising biotech company with innovative drug delivery technology. Its success hinges on clinical trial outcomes and expanding licensing agreements. The company needs to focus on securing partnerships and generating revenue. Competition from larger pharmaceutical companies and regulatory hurdles pose ongoing challenges.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Lexaria Bioscience Corp. website
- Company filings (SEC)
- Industry reports
- Press releases
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data is estimated and may not be precise. This is for informational purposes only. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lexaria Bioscience Corp
Exchange NASDAQ | Headquaters Kelowna, BC, Canada | ||
IPO Launch date 2006-10-10 | CEO & Director Mr. Richard C. Christopher | ||
Sector Healthcare | Industry Biotechnology | Full time employees 7 | Website https://lexariabioscience.com |
Full time employees 7 | Website https://lexariabioscience.com | ||
Lexaria Bioscience Corp. operates as a biotechnology company. It offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules, including glucagon-like peptide-1 drugs (GLP-1) and glucose -dependent insulinotropic polypeptide drugs (GIP), vitamins, pain medications, hormones, phosphodiesterase type 5 (PDE5) inhibitors, antivirals, nicotine and its analogs, and cannabinoids. Its DehydraTECH technology is applied to various therapeutic indications, such as diabetes, weight loss, hypertension, and heart disease; is implemented in a multitude of ingestible or topically administered product formats comprising oral suspensions, tablets, capsules, foods, beverages, creams, lotions, and skin patches; and is suitable for a variety of product formats, including pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.